Abstract: A chair with a transom, a seat support, a back portion, and a combined rock and recline mechanism. The combined rock and recline mechanism has front and rear rocking arrangements configured to enable the seat support and back portion to together rock generally forward and rearward from a neutral position relative to the transom, and a recline arrangement that is configured such that the seat support is in a first at-rest position relative to the back portion when the back portion is in an upright position, and such that reclining the back portion rearwardly from the upright position toward a reclined position moves the seat support upward and rearward from the first at-rest position.

Abstract: A system for moving cargo is disclosed. The system includes a cart, which, in turn, includes a body with a battery compartment and a platform. The cart also includes wheels and a motor for driving the wheels. A battery is housed in the battery compartment for powering the motor. The system also includes a cargo carrier mounted on the platform. The cargo carrier includes a base, two side walls, and two end walls. At least one end wall or side wall is adapted to be moved between different positions to change the shape and/or size of the compartment.

Abstract: Disclosed is a heavy metal adsorbing mixture that sequesters heavy metals such as lead from water. The mixture is formed from two of more lead sorbents. The lead sorbents exhibit a synergistic effect such that the lead adsorption of the mixture of materials is greater than the theoretical maximum absorption of the individual components of the mixture. Mixtures of lead sorbents that exhibit synergistic lead adsorption are characterized by elemental compositions within specified ranges by weight, as measured by x-ray fluorescence.

Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.

Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.

Abstract: In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.

Abstract: In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.

Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.

Abstract: Pharmaceutical formulations in the form of a powder for suspension comprising at least one proton pump inhibitor in micronized form; at least one antacid; and at least one suspending agents are provided herein. Also provided herein are methods for making and using pharmaceutical formulations comprising at least one proton pump inhibitor and at least one antacid.

Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.

Abstract: The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties.

Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.

Abstract: A solar heat collection element includes: a central tube (102) formed from glass-ceramic material; and an outer tube (104) formed from glass material disposed coaxially with respect to the central tube (102) to form a volume therebetween (106).

Abstract: Textured superstrates for photovoltaic cells, for example, silicon tandem photovoltaic cells with light scattering properties which are sufficient for light trapping independent of wavelength are described herein. Features of a textured surface of a superstrate, via the method(s) used to make the textured superstrate, can be tailored to provide the desired light scattering/trapping properties. The method includes grinding and lapping or grinding, lapping, and etching of a glass superstrate.

Abstract: Light scattering substrates, superstrates, and/or layers for photovoltaic cells are described herein. Such structures can be used for volumetric scattering in thin film photovoltaic cells.

Abstract: A solar heat collection element includes: a central tube (102) formed from glass-ceramic material; and an outer tube (104) formed from glass material disposed coaxially with respect to the central tube (102) to form a volume therebetween (106).

Abstract: Pharmaceutical formulations in the form of a powder for suspension comprising at least one proton pump inhibitor in micronized form; at least one antacid; and at lest one suspending agents are provided herein. Also provided herein are methods for making and using pharmaceutical formulations comprising at least one proton pump inhibitor and at least one antacid.

Abstract: The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties.

Abstract: Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent, a sleep aid and acetaminophen, ibuprofen, aspirin or naproxen are described. Methods are described for treating gastric acid related disorders and inducing sleep, using pharmaceutical compositions comprising a proton pump inhibitor, a buffering agent, a sleep aid and a pain reliever.

Abstract: In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.